What does Field Medical do?
Field Medical is a cardiac pulsed field ablation technology company that develops the FieldForce Ablation System to treat a wide range of cardiac arrhythmias, including ventricular tachycardia and atrial fibrillation.
How much did they raise?
The company raised $40M in a Series A round, combining $20M in new capital with $20M in converted seed-round debt, with participation from strategics, venture capital firms, family offices, and reinvesting seed investors.
What are their plans for the money?
Field Medical plans to use the funds to complete two pilot studies—VCAS for ventricular tachycardia and Field PULSE for atrial fibrillation—further develop its commercial PFA system, scale operations, and prepare for its pivotal VERITAS trial, potentially transforming cardiac arrhythmia treatment.
What have they achieved so far?
The company has demonstrated promising pilot study results with its FieldForce Ablation System and received Breakthrough Device Designation from the FDA in 2024, along with inclusion in the TAP Pilot Program.
